Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will report first quarter 2026 financial results after the close of trading on Wednesday, April 29, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a live and archived webcast available in the Investors section of the Pulmonx website.
Positive
- None.
Negative
- None.
News Market Reaction – LUNG
In the Apr 16 session, LUNG declined 2.67%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 20 | Earnings date notice | Neutral | +6.0% | Set Q4 and full-year 2025 report date with call and webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling news on Feb 20, 2026 coincided with a positive 5.99% move, hinting that timing announcements can draw investor attention.
Recent news flow featured an earlier earnings date notice on Feb 20, 2026 for fourth quarter and full-year 2025 results, which saw a 5.99% next-day move. That event highlighted management’s practice of pre-announcing reporting dates with a standard conference call and webcast setup. Today’s first quarter 2026 earnings date announcement continues this pattern of providing clear timing for financial disclosures and investor communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
